Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: Results from a prospective 12-month nonrandomized unblinded clinical trial

Journal of Rheumatology

Volumn 38, Issue 11, 2011, Pages 2466-2474

  Karanikolas, George N ^a   Koukli, Eftyhia Maria ^b   Katsalira, Aikaterini ^c   Arida, Aikaterini ^a   Petrou, Dimitrios ^d   Komninou, Eleni ^e   Fragiadaki, Kalliopi ^a   Zacharioudaki, Anna ^f   Lasithiotakis, Ioannis ^f   Giavri, Eirini ^a   Vaiopoulos, George ^a   Sfikakis, Petros P ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b First IKA Hospital   (Greece)

^c Laboratories for Research of the Musculoskeletal System   (Greece)

^d Department of Rheumatology and Clinic of Osteoporosis   (Greece)

^e IASO GENERAL HOSPITAL   (Greece)

^f Hellenic Rheumatology Society   (Greece)

Author keywords

Adalimumab; Combination drug therapy; Cyclosporine; Drug resistance; Psoriatic arthritis

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; HYPERTENSION; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; PSORIATIC ARTHRITIS; TREATMENT FAILURE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; CYCLOSPORINE; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80155181444     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110242     Document Type: Article

References (33)

1. Chandran V. Epidemiology of psoriatic arthritis. J Rheumatol 2009;36:213-5.
2. Rahman P, Nguyen E, Cheung C, Schentag CT, Gladman DD. Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis. J Rheumatol 2001;28:1041-4. (Pubitemid 32422586)
3. Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998;41:1103-10. (Pubitemid 28265412)
4. Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 2006; 33:1422-30. (Pubitemid 44025163)
5. Antoni CE, Kavanaugh A, van der Heijde DM, Beutler A, Keenan G, Zhou B, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008;35:869-76. (Pubitemid 351747130)
6. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89. (Pubitemid 41447111)
7. Mease PJ, Ory P, Sharp JT, Ritchlin CT, van den Bosch F, Wellborne F, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009;68:702-9.
8. Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 2005 Mar;64 Suppl 2:ii74-7. (Pubitemid 40288528)
9. Fraser AD, van Kuijk AW, Westhovens R, Karim Z, Wakefield R, Gerards AH, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005;64:859-64. (Pubitemid 40733909)
10. Salvarani C, Boiardi L, Macchioni P, Pipitone N, Catanoso M, Pigatto P. Multidisciplinary focus on Cyclosporin A. J Rheumatol Suppl 2009 Aug;83:52-5.
11. Daly M, Alikhan A, Armstrong AW. Combination systemic therapies in psoriatic arthritis. J Dermatolog Treat 2010 Jul 28. [E-pub ahead of print]
12. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73. (Pubitemid 44205029)
13. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2013-20.
14. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
15. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
16. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
17. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157:238-44. (Pubitemid 8387357)
18. Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003;49:206-12. (Pubitemid 36951265)
19. Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010;69:1441-7.
20. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387-94.
21. Strand V, Cohen S, Crawford B, Smolen JS, Scott DL. Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis. Rheumatology 2004;43:640-7. (Pubitemid 38628197)
22. Pincus T, Sokka T, Wolfe F. Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum 2001;44:1234-6. (Pubitemid 32537519)
23. Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001;28:1842-6. (Pubitemid 32726931)
24. Gladman DD, Sampalis JS, Illouz O, Guerette B. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study. J Rheumatol 2010;37:1898-906.
25. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851-64. (Pubitemid 351509657)
26. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158:558-66. (Pubitemid 351239154)
27. Heydendael VM, Spuls PI, Opmeer BC, de Borgie CA, Reitsma JB, Goldschmidt WF, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003;349:658-65. (Pubitemid 36975998)
28. D'Angelo S, Cutro MS, Lubrano E, Leccese P, Mennillo GA, Ferrara N, et al. Combination therapy with ciclosporin and etanercept in patients with psoriatic arthritis. Ann Rheum Dis 2010;69:934-5.
29. Atzeni F, Boccassini L, Antivalle M, Salaffi F, Sarzi-Puttini P. Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study. Ann Rheum Dis 2011;70:712-4.
30. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72. (Pubitemid 38924405)
31. Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007;56:476-88.
32. Virkki LM, Sumathikutty BC, Aarnio M, Valleala H, Heikkila R, Kauppi M, et al. Biological therapy for psoriatic arthritis in clinical practice: outcomes up to 2 years. J Rheumatol 2010;37:2362-8.
33. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86.